Highest-materiality recent filing
Monte Rosa Q2 2026 net loss $43.4M; cash $626M; MRT-8102 GFORCE-1 readout H2 2026
Net loss of $43.4M in Q2 2026 vs $12.3M in Q2 2025; collaboration revenue $9.0M vs $23.2M.
Monte Rosa Q1 net loss $44.5M; cash $671M; multiple pipeline advances
Net loss of $44.5M vs net income of $46.9M in Q1 2025; collaboration revenue fell to $4.2M from $84.9M.
Q4 net loss $46.1M vs $13.4M in Q4 2024; full-year net loss decreased to $38.6M from $72.7M.
Monte Rosa prices $300M public offering of common stock and pre-funded warrants
Offering of 11,125,000 shares at $24.00/share and pre-funded warrants for 1,375,000 shares at $23.9999 each.
Monte Rosa reports positive interim Phase 1 data for MRT-8102; hsCRP reduced 85% in 4 weeks
In subjects with elevated CVD risk, MRT-8102 reduced hsCRP by 85% after 4 weeks; 94% achieved hsCRP <2 mg/L (median baseline 6.3 mg/L).
MRT-2359 + enzalutamide shows 100% PSA response in AR-mutant mCRPC; Phase 2 planned 2026
In 14 evaluable mCRPC patients, overall DCR 64% (9/14); in AR-mutant subset (n=4), 100% PSA response rate and 100% DCR, with 2 RECIST partial responses.
Monte Rosa reports Q3 net loss $27.1M; second Novartis deal with $120M upfront
Net loss $27.1M vs $23.9M YoY; collaboration revenue $12.8M (vs $9.2M).
Monte Rosa and Novartis expand collaboration for immune-disease degraders; upfront $120M
Monte Rosa receives $120M upfront from Novartis under new collaboration for degraders in immune-mediated diseases.
Monte Rosa Q2 net loss narrows to $12.3M on $23.2M collaboration revenue; cash runway to 2028
Collaboration revenue $23.2M (vs $4.7M YoY) from Novartis license; net loss improved to $12.3M from $30.3M.
Monte Rosa Q1 net income $46.9M on Novartis revenue; pipeline advances
Net income of $46.9M vs net loss of $32.0M a year ago; collaboration revenue $84.9M from Novartis.
Monte Rosa Q4 net income $13.4M; Ph1 MRT-6160 >90% VAV1 deg, MRT-2359 CRPC response
Q4 2024 net income $13.4M vs net loss $33.3M in Q4 2023; collaboration revenue $60.6M from Novartis/Roche deals.
Monte Rosa sets RP2D for MRT-2359 at 0.5 mg/day 21/7 schedule; safety, PD data positive
RP2D selected: 0.5 mg daily on 21-days-on/7-days-off schedule based on favorable safety and ~60% GSPT1 degradation.
Monte Rosa reports Q3 net loss $23.9M; announces Novartis deal for VAV1 degraders with $150M upfront
Net loss of $23.9M for Q3 2024; collaboration revenue of $9.2M from Roche.
Monte Rosa licenses VAV1 degrader MRT-6160 to Novartis for $150M upfront
Novartis gets exclusive worldwide rights to develop, manufacture, and commercialize VAV1 MGDs including MRT-6160.
Monte Rosa Q2 net loss $30.3M; cash $267.1M; IND cleared for MRT-6160
Net loss $30.3M for Q2 2024 vs $32.0M in Q1; collaboration revenue $4.7M from Roche deal.
Monte Rosa: MRT-2359 dose update; MRT-6160 IND for autoimmune diseases
MRT-2359 Phase 1/2: favorable safety at 0.5 mg 21/7 schedule; evaluating 0.75 mg cohort; RP2D and updated data expected H2 2024.
Monte Rosa prices $100M public offering of common stock and pre-funded warrants
Priced 10.6M shares at $4.70/share and pre-funded warrants for 10.6M shares at $4.6999/warrant; gross proceeds $100M.
Monte Rosa Q1 net loss $32M; pipeline advances with MRT-2359, MRT-6160, MRT-8102 milestones
Q1 2024 net loss $32.0M; cash $197.8M (down from $237.0M Dec 2023), sufficient into H1 2026.
Monte Rosa CSO Owen Wallace departs May 17 to become CEO at UK biotech; remains adviser
Owen Wallace resigns as CSO effective May 17, 2024, to become CEO of a UK-based biotech company.
Monte Rosa reports Q4 2023 net loss $33.3M; cash into H1 2026; key pipeline milestones on track
Net loss Q4 2023 $33.3M ($30.8M prior year); FY net loss $135.4M; cash $237M, runway into H1 2026.
Monte Rosa outlines 2024 milestones: Fast Track for MRT-2359, MRT-6160 Phase 1, cash into H1 2026
FDA Fast Track Designation for MRT-2359 in previously treated metastatic SCLC with L-MYC or N-MYC expression.
Monte Rosa Q3 net loss $34.9M; cash runway into H1 2026 after Roche deal and $25M offering
Net loss $34.9M vs $27.3M in Q3 2022; R&D expenses $28.3M, G&A $8.7M.
Monte Rosa raises $25M via pre-funded warrant offering at $2.4999 per share
Gross proceeds ~$25M from sale of pre-funded warrants to purchase 10,000,400 shares.
Monte Rosa signs $50M upfront Roche collaboration for MGDs; MRT-2359 shows early efficacy
Upfront payment of $50M from Roche; potential milestones >$2B for initial oncology/neurology targets.
Monte Rosa Q2 net loss $35.2M, CFO resigns; cash sustains into 2025
Net loss of $35.2M for Q2 2023 vs $26.5M in Q2 2022; R&D expenses $29.1M.
Monte Rosa Q1 net loss $32M; cash $237M; MRT-2359 data on track for H2 2023
Net loss $32M in Q1 2023 vs $23.9M in Q1 2022; R&D expenses $26.8M vs $17.9M.
Monte Rosa reports FY 2022 net loss of $108.5M; MRT-2359 Phase 1/2 data expected H2 2023
FY 2022 net loss $108.5M (vs $74.0M in 2021); cash & securities $268.1M, runway into 2025.
Monte Rosa Therapeutics outlines 2023 milestones; MRT-2359 Fast Track designation from FDA
MRT-2359 granted FDA Fast Track for previously treated metastatic NSCLC with L-MYC or N-MYC expression.
Monte Rosa Q3 net loss $27.3M; MRT-2359 Phase 1/2 dosing initiated
Net loss of $27.3M in Q3 2022 vs $19.8M in Q3 2021; R&D expenses rose to $21.3M.
Monte Rosa Q2 2022 net loss $26.5M; IND submitted for MRT-2359
Net loss of $26.5M for Q2 2022, compared to $18.4M in Q2 2021.
Monte Rosa Q1 net loss $23.9M; IND for MRT-2359 expected mid-2022
Net loss $23.9M for Q1 2022 vs $12.3M in Q1 2021; R&D spend $17.9M.
Monte Rosa Therapeutics enters 128-month lease for 63,327 sq ft in Boston at $95/sqft base rent
Leased 63,327 sq ft at 321 Harrison Ave, Boston for office/lab space; term starts April 1, 2022.
Monte Rosa names first development candidate MRT-2359 targeting GSPT1; Q3 net loss $19.8M
Selected MRT-2359 as first development candidate; initiated IND-enabling studies for mid-2022 IND submission.
Monte Rosa Q2 net loss $18.4M; $255.6M IPO extends cash into late 2024
R&D expenses $14.6M (Q2 2020: $4.9M), G&A $3.5M ($0.5M) as headcount and lab activities expanded.
On May 28, 2024, the Compensation, Nomination and Corporate Governance Committee of Board of Directors of Monte Rosa Therapeutics, Inc. (the “Company”) promoted Jennifer Champoux, the Company’s Chief People and Operations Officer, to serve as the Company’s Chief Operating Officer, effective as of May 28, 2024
On April 29, 2024, Owen Wallace, the Chief Scientific Officer of Monte Rosa Therapeutics, Inc. (the "Company"), resigned from the Company effective May 17, 2024 (the “Effective Date”).
the Board appointed Anthony M. Manning, Ph.D. to fill the newly created vacancy on the Board resulting from an increase in the size of the Board from eight (8) to nine (9) directors.
the Board appointed Jan Skvarka, Ph.D., MBA to join the Board, effective as of March 23, 2023.
Max materiality 0.90 · Median 0.60 · Most common event earnings